Bicara CEO sells 15K shares after option exercises
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported option exercises and a modest share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported option exercises and a modest share sale. She exercised options to acquire a total of 37,760 shares of common stock at exercise prices of $3.7898, $4.4369, and $5.4537 per share, converting derivative awards into stock.
On the same date, she sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $23.6097 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. After these transactions, she directly owns 362,152 shares of Bicara common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
9 txns
Insider
Mazumdar Claire
Role
Chief Executive Officer
Sold
15,000 shs ($354K)
Approx. gross sale proceeds
$354K
Approx. exercise cost
$160K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $3.7898 | $57K |
| Sale | Common Stock | 15,000 | $23.6097 | $354K |
| Exercise | Stock Option (Right to Buy) | 8,226 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 7,454 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 7,080 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,226 | $4.4369 | $36K |
| Exercise | Common Stock | 7,454 | $3.7898 | $28K |
| Exercise | Common Stock | 7,080 | $5.4537 | $39K |
Holdings After Transaction:
Stock Option (Right to Buy) — 906,769 contracts (Direct);
Common Stock — 362,152 shares (Direct)
Footnotes (6)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.355 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date.
- F4. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
- F5. The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.
- F6. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 15,000 shares
Sale price: $23.6097 per share
Shares acquired via exercises: 37,760 shares
+5 more
8 metrics
Shares sold
15,000 shares
Open-market sale of common stock at weighted average price
Sale price
$23.6097 per share
Weighted average sale price for 15,000 BCAX shares
Shares acquired via exercises
37,760 shares
Common stock obtained through option exercises
Post-transaction holdings
362,152 shares
BCAX common shares directly owned after transactions
Option strike price
$3.7898 per share
Exercise price for one option grant converted to common stock
Option strike price
$4.4369 per share
Exercise price for a second option grant exercised
Option strike price
$5.4537 per share
Exercise price for a third option grant exercised
10b5-1 plan adoption date
February 12, 2025
Date CEO’s pre-arranged trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting in sixteen equal quarterly installments financial
"The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BCAX CEO Claire Mazumdar report on this Form 4?
Claire Mazumdar reported exercising stock options to acquire 37,760 Bicara Therapeutics common shares and selling 15,000 shares in the open market. These combined moves convert option awards into stock while monetizing a portion of her holdings, all disclosed in a single Form 4 filing.
Were the BCAX CEO’s stock sales made under a Rule 10b5-1 trading plan?
Yes. The Form 4 states the 15,000-share sale was executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary, market-timed insider transactions.
What option awards did the BCAX CEO exercise in this Form 4?
She exercised stock options covering 37,760 shares at exercise prices of $3.7898, $4.4369, and $5.4537. Related footnotes explain these options vest in sixteen equal quarterly installments beginning in 2022 and 2023, contingent on her continued service with Bicara Therapeutics.
What does the weighted average sale price mean in the BCAX Form 4?
The weighted average sale price of $23.6097 reflects many trades between $23.355 and $23.81. Rather than listing each execution separately, the filing presents one blended figure, while offering to provide detailed trade-by-trade pricing information to the issuer, shareholders, or regulators upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates